Cited by 234Substance Abuse Treatment and OutcomesOpioid Use Disorder TreatmentNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Bupropion for the Treatment of Methamphetamine Dependence

Elkashef, Ahmed M, Rawson, Richard A, Anderson, Ann L, Li, Shou-Hua, Holmes, Tyson, Smith, Edwina V, Chiang, Nora, Kahn, Roberta, Vocci, Frank, Ling, Walter, Pearce, Valerie J, McCann, Michael, Campbell, Jan, Gorodetzky, Charles, Haning, William, Carlton, Barry, Mawhinney, Joseph, Weis, Dennis·2008·Neuropsychopharmacology

DOI 10.1038/sj.npp.1301481

Open this paper in CoChat — free account

Abstract

Bupropion was tested for efficacy in increasing weeks of abstinence in methamphetamine-dependent patients, compared to placebo. This was a double-blind placebo-controlled study, with 12 weeks of treatment and a 30-day follow-up. Five outpatient substance abuse treatment clinics located west of the Mississippi participated in the study. One hundred and fifty-one treatment-seekers with DSM-IV diagnosis of methamphetamine dependence were consented and enrolled. Seventy-two participants were randomized to placebo and 79 to sustained-release bupropion 150 mg twice daily. Patients were asked to come to the clinic three times per week for assessments, urine drug screens, and 90-min group psychotherapy. The primary outcome was the change in proportion of participants having a methamphetamine-free week. Secondary outcomes included: urine for quantitative methamphetamine, self-report of methamphetamine use, subgroup analyses of balancing factors and comorbid conditions, addiction severity, craving, risk behaviors for HIV, and use of other substances. The generalized estimating equation regression analysis showed that, overall, the difference between bupropion and placebo groups in the probability of a non-use week over the 12-week treatment period was not statistically significant (p=0.09). Mixed model regression was used to allow adjustment for baseline factors in addition to those measured (site, gender, level of baseline use, and level of symptoms of depression). This subgroup analysis showed that bupropion had a significant effect compared to placebo, among male patients who had a lower level of methamphetamine use at baseline (p<0.0001). Comorbid depression and attention-deficit/hyperactivity disorder did not change the outcome. These data suggest that bupropion, in combination with behavioral group therapy, was effective for increasing the number of weeks of abstinence in participants with low-to-moderate methamphetamine dependence, mainly male patients, regardless of their comorbid condition.

Integrity signals

Registry

Crossref · 10.1038/sj.npp.1301481

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,385
Statistical Analysis with Missing Data
Little, R. J. A., & Rubin, D. B. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781119013563 · Cited by 8,473
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
Structured Clinical Interview for DSM-IV Axis I Disorders
Spitzer, R. L., First, M. B., & Gibbon, M. (1997) · Medical Entomology and Zoology · Cited by 3,582
Untitled work
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115
Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.
Aickin, M., & Gensler, H. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.5.726 · Cited by 1,346
Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence
Volkow, N. D., Chang, L. L., Wang, G., Fowler, J. S., Franceschi, D., Sedler, M. J., Gatley, S. J., Miller, E. N., HITZEMANN, R. J., Ding, Y., et al. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09414.2001 · Cited by 754

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 1

Somoza E, Baker S, Himmler C, LoCastro J, Mezinskis J, Simon S et al (2000). The brief substance craving scale—measuring craving in a clinical trial. Presented at the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence, 1999. NIDA Res Monogr 180: 304.

Sorted by citations

Substance Abuse in Women
Greenfield, S. F., Back, S. E., Lawson, K., & Brady, K. T. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.01.004 · Cited by 602
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432
Treatment of internet addiction: a meta-analysis
Winkler, A., Dörsing, B., Rief, W., Shen, Y., & Glombiewski, J. A. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2012.12.005 · Cited by 404
The Methamphetamine Problem in the United States
Gonzales, R. E., Mooney, L. J., & Rawson, R. A. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103600 · Cited by 358
Bupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Methamphetamine Psychosis: Epidemiology and Management
Glasner-Edwards, S., & Mooney, L. J. (2014) · CNS Drugs · doi:10.1007/s40263-014-0209-8 · Cited by 266
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242
Modafinil for the treatment of cocaine dependence
Anderson, A. L., Reid, M. S., Li, S.-H., Holmes, T., Shemanski, L., Slee, A., Smith, E. V., Kahn, R., Chiang, N., Vocci, F., et al. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.015 · Cited by 235
“Our results are in line with those from other recent clinical trials for treatment of stimulant dependence (Kampman et al., 2004; Elkashef et al., 2008), where no single medication has been shown to help most patients, but rather, some subgroups seem to respond to a specific medication.”
ResultSelf-citation
Improving translation of animal models of addiction and relapse by reverse translation
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175
Attention Deficit/Hyperactivity Disorder and Substance Abuse: Diagnostic and Therapeutic Considerations
SULLIVAN, M. A., & RUDNIK‐LEVIN, F. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05783.x · Cited by 172
Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Cocaine Addiction
Carroll, F. I., Blough, B. E., Abraham, P., Mills, A. C., Holleman, J. A., Wolckenhauer, S. A., Decker, A. M., Landavazo, A., McElroy, K. T., Navarro, H. A., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901189z · Cited by 158
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
New developments on the neurobiological and pharmaco-genetic mechanisms underlying internet and videogame addiction
Weinstein, A. M., & Lejoyeux, M. (2013) · American Journal on Addictions · doi:10.1111/ajad.12110 · Cited by 180
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
SHOPTAW, S. J., Heinzerling, K. G., Rotheram-Fuller, E. J., Steward, T., Wang, J., Swanson, A., Garza, R. D. L., Newton, T., & Ling, W. W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.010 · Cited by 150
Pharmacotherapy of amphetamine‐type stimulant dependence: An update
Brensilver, M., Heinzerling, K. G., & SHOPTAW, S. J. (2013) · Drug and Alcohol Review · doi:10.1111/dar.12048 · Cited by 125
Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Smoking Cessation
Carroll, F. I., Blough, B. E., Mascarella, S. W., Navarro, H. A., Eaton, J. B., Lukas, R. J., & Damaj, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9017465 · Cited by 119
Modafinil for the treatment of methamphetamine dependence
Anderson, A. L., Li, S.-H., Biswas, K., McSherry, F., Holmes, T. H., Iturriaga, E., Kahn, R., Chiang, N., Beresford, T. P., Campbell, J. L., et al. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.007 · Cited by 117
Self-citation
Topiramate for the treatment of methamphetamine addiction: a multi‐center placebo‐controlled trial
Elkashef, A. M., Kahn, R., Yu, E., Iturriaga, E., Li, S., Anderson, A., Chiang, N., Ait‐Daoud, N., Weiss, D., McSherry, F., et al. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03771.x · Cited by 116
Self-citation
Pharmacotherapeutic agents in the treatment of methamphetamine dependence
Morley, K. C., Cornish, J. L., Faingold, A., Wood, K., & Haber, P. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313229 · Cited by 111
Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
A Randomized, Placebo-Controlled Trial of Sustained-Release Dextroamphetamine for Treatment of Methamphetamine Addiction
Galloway, G., Buscemi, R., Coyle, J., Flower, K., Siegrist, J. D., Fiske, L. A., Baggott, M., Li, L., Polcin, D., Chen, C.-Y. A., et al. (2010) · Clinical pharmacology and therapy · doi:10.1038/clpt.2010.307 · Cited by 103
Chronic methamphetamine self-administration disrupts cortical control of cognition
Bernheim, A. P., See, R. E., & Reichel, C. M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.07.020 · Cited by 99
Agonist‐like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies
Herin, D. V., Rush, C. R., & Grabowski, J. G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05145.x · Cited by 101
Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts.
Radfar, S. R., & Rawson, R. A. (2014) · PubMed Central · Cited by 97
Efficacy of psychostimulant drugs for amphetamine abuse or dependence.
Pérez-Mañá, C., Castells, X., Torrens, M., Capellà, D., & Farré, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009695.pub2 · Cited by 114
Treatments for Methamphetamine Abuse
Brackins, T., Brahm, N. C., & Kissack, J. C. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426557 · Cited by 96
Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care
Rawson, R. A., Chudzynski, J. E., Mooney, L. J., Gonzales, R. E., Ang, A., Dickerson, D. L., Peñate, J., Salem, B. A., Dolezal, B. A., & Cooper, C. B. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.029 · Cited by 92
A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.
Carpenter, K. M., McDowell, D., Brooks, D. J., Cheng, W. Y., & Levin, F. R. (2009) · The American Journal on Addictions · doi:10.1080/10550490802408936 · Cited by 89
. A pilot trial of integrated behavioral activation and sexual risk reduction counseling for HIV-uninfected men who have sex with men abusing crystal methamphetamine.
Mimiaga, M. J., Reisner, S. L., Pantalone, D. W., O'Cleirigh, C., Mayer, K. H., & Safren, S. A. (2012) · AIDS Patient Care and STDs · doi:10.1089/apc.2012.0216 · Cited by 84
Clinical Pharmacology During Pregnancy
(2013) · Elsevier eBooks · doi:10.1016/c2010-0-67194-x · Cited by 84
Bupropion improves attention but does not affect impulsive behavior in healthy young adults.
Acheson, A., & de Wit, H. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.16.2.113 · Cited by 82
Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usual
McGregor, C., Srisurapanont, M., Mitchell, A., Wickes, W., & White, J. M. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.12.003 · Cited by 82
Pharmacotherapy for amphetamine dependence: A systematic review.
Lee, N., Jenner, L., Harney, A., & Cameron, J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.06.038 · Cited by 70
Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder
Ling, W. W., Chang, L., Hillhouse, M. P., Ang, A., Striebel, J. M., Jenkins, J., Hernandez, J. C., Olaer, M., Mooney, L. J., Reed, S. W., et al. (2014) · Addiction · doi:10.1111/add.12608 · Cited by 81
The neurobiological mechanisms of physical exercise in methamphetamine addiction
Morais, A., Pita, I. R., Ribeiro, C., & Pereira, F. C. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12788 · Cited by 78
Dark Times: The Role of Negative Reinforcement in Methamphetamine Addiction
May, A. C., Aupperle, R. L., & Stewart, J. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00114 · Cited by 84
The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans
Olive, M. F., Taylor, & Lewis (2013) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s39684 · Cited by 87
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Psychostimulant addiction treatment
Phillips, K. A., Epstein, D. H., & Preston, K. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.04.002 · Cited by 75
A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74
Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use
Rawson, R. A. (2013) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2013.09.039 · Cited by 71
Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial
Anderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70
Self-citation
Anti-relapse medications: Preclinical models for drug addiction treatment
Yahyavi-Firouz-Abadi, N., & See, R. (2009) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2009.06.014 · Cited by 74
Higher diffusion in striatum and lower fractional anisotropy in white matter of methamphetamine users
Alicata, D., Chang, L., Cloak, C. C., Abe, K. A., & Ernst, T. (2009) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2009.03.011 · Cited by 68
Bupropion and Bupropion Analogs as Treatments for CNS Disorders
Carroll, F. I., Blough, B. E., Mascarella, S. W., Navarro, H. A., Lukas, R. J., & Damaj, M. I. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00005-6 · Cited by 67
Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use
Heinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014) · Addiction · doi:10.1111/add.12636 · Cited by 64
For What Diagnoses Are Psychotropic Medications Being Prescribed?
Mark, T. L. (2010) · CNS Drugs · doi:10.2165/11533120-000000000-00000 · Cited by 64
Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers
Garza, R. D. L., Zorick, T. S., London, E. D., & Newton, T. F. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.08.013 · Cited by 63
Amphetamines, the pregnant woman and her children: a review
Oei, J. L., Kingsbury, A. M., Dhawan, A., Burns, L., Feller, J. M., Clews, S., Falconer, J., & Abdellatif, M. (2012) · Journal of Perinatology · doi:10.1038/jp.2012.59 · Cited by 64
New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders
Newman, A. H., Ku, T. C., Jordan, C. J., Bonifazi, A., & Xi, Z. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-124205 · Cited by 62
Provigil (Modafinil) Plus Cognitive Behavioral Therapy for Methamphetamine Use in HIV+ Gay Men: A Pilot Study
McElhiney, M. C., Rabkin, J. G., Rabkin, R., & Nunes, E. V. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802342907 · Cited by 61
“Pharmacologic trials conducted with MA users have included selegeline, ondansetron, paroxetine (6), bupropion (7), and sertraline (8), usually accompanied by a structured therapy.”
Background
Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers
Newton, T. F., Reid, M. S., Garza, R. D. L., Mahoney, J. J., Abad, A., Condos, R., Palamar, J. J., Halkitis, P. N., Mojisak, J., Anderson, A., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009097 · Cited by 61
Self-citation
Management of methamphetamine abuse and dependence
Ling, W., Rawson, R., & Shoptaw, S. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0035-x · Cited by 60
Agonist Replacement for Stimulant Dependence: A Review of Clinical Research
Stoops, W. W., & Rush, C. (2013) · Current pharmaceutical design · doi:10.2174/138161281940131209142843 · Cited by 65
A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period
Bisaga, A. M., Aharonovich, E., Cheng, W. Y., LEVIN, F. R., Mariani, J. J., Raby, W. N., & Nunes, E. V. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.04.006 · Cited by 59
A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence
Brown, E. S., & Gabrielson, B. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.006 · Cited by 58
The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers
Garza, R. D. L., Mahoney, J. J., Culbertson, C., SHOPTAW, S. J., & Newton, T. F. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.12.010 · Cited by 58
Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis
Bhatt, M., Zielinski, L., Baker-Beal, L., Bhatnagar, N., Mouravska, N., Laplante, P., Worster, A., Thabane, L., & Samaan, Z. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0370-x · Cited by 56
Psychological treatment for methamphetamine use and associated psychiatric symptom outcomes: A systematic review
Stuart, A. M., Baker, A. L., Denham, A. M. J., Lee, N. K., Hall, A., Oldmeadow, C., Dunlop, A., Bowman, J., & McCarter, K. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.09.005 · Cited by 49
A review of treatment options for co-occurring methamphetamine use disorders and depression
Hellem, T. L., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000058 · Cited by 51
Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects
Schmid, Y., Rickli, A., Schaffner, A., Duthaler, U., Grouzmann, E., Hysek, C. M., & Liechti, M. E. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222356 · Cited by 51
Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1100471 · Cited by 49
The relationship between methamphetamine and alcohol use in a community sample of methamphetamine users
Bujarski, S., Roche, D. J. O., Lunny, K. F., Moallem, N. R., Courtney, K. E., Allen, V. C., Hartwell, E. E., Leventhal, A. M., Rohrbaugh, T., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.06.004 · Cited by 47
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials
Amin‐Esmaeili, M., Farokhnia, M., Susukida, R., Leggio, L., Johnson, R. M., Crum, R. M., & Mojtabai, R. (2024) · Addiction · doi:10.1111/add.16409 · Cited by 43
Bupropion attenuates methamphetamine self-administration in adult male rats
Reichel, C. M., Murray, J. E., Grant, K. M., & Bevins, R. A. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.09.006 · Cited by 46
Psychostimulants: Basic and Clinical Pharmacology.
McCreary, A., Müller, C., & Filip, M. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.02.008 · Cited by 40
Compulsive methamphetamine taking under punishment is associated with greater cue-induced drug seeking in rats
Torres, O. V., Jayanthi, S., Ladenheim, B., McCoy, M. T., Krasnova, I. N., & Cadet, J. L. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.03.009 · Cited by 44
A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: Suggested guidelines for treatment discontinuation/augmentation
Brensilver, M., Heinzerling, K. G., Swanson, A., & SHOPTAW, S. J. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.03.027 · Cited by 43
3,4‐Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine‐induced damage to dopamine nerve endings: β‐ketoamphetamine modulation of neurotoxicity by the dopamine transporter
Anneken, J. H., Angoa‐Pérez, M., & Kuhn, D. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13048 · Cited by 42
A Novel, Nonbinary Evaluation of Success and Failure Reveals Bupropion Efficacy Versus Methamphetamine Dependence: Reanalysis of a Multisite Trial
McCann, D. J., & Li, S. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00263.x · Cited by 41
Neuropharmacology of addiction and how it informs treatment
Lingford-Hughes, A. R., Watson, B. J., Kalk, N. J., & Reid, A. G. (2010) · British Medical Bulletin · doi:10.1093/bmb/ldq032 · Cited by 42
Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings
Härtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-105500 · Cited by 39
Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment
Brensilver, M., Heinzerling, K. G., Swanson, A., Telesca, D., Furst, B. A., & SHOPTAW, S. J. (2012) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2012.00423.x · Cited by 39
Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence
Simmler, L. D., Wandeler, R., & Liechti, M. E. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-220 · Cited by 38
Patterns of methamphetamine use and symptoms of depression among young adults in northern Thailand
Sutcliffe, C. G., German, D., Sirirojn, B., Latkin, C. A., Aramrattana, A., Sherman, S. G., & Celentano, D. D. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.11.014 · Cited by 38
Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers
Garza, R. D. L., SHOPTAW, S. J., & Newton, T. F. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008456 · Cited by 38
Drum-Assisted Recovery Therapy for Native Americans (DARTNA): Results from a Pretest and Focus Groups
Dickerson, D., Venner, K., Duran, B., Annon, J., Hale, B., & Funmaker, G. (2014) · American Indian and Alaska Native Mental Health Research · doi:10.5820/aian.2101.2014.35 · Cited by 36
Bupropion differentially impacts acquisition of methamphetamine self-administration and sucrose-maintained behavior
Reichel, C. M., Linkugel, J. D., & Bevins, R. A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.02.002 · Cited by 36
The Search for Medications to Treat Stimulant Dependence
Kampman, K. M. (2008) · Addiction Science & Clinical Practice · doi:10.1151/ascp084228 · Cited by 36
Double‐blind placebo‐controlled evaluation of the PROMETA™ protocol for methamphetamine dependence
Ling, W. W., SHOPTAW, S. J., Hillhouse, M. P., Bholat, M. A., Charuvastra, C., Heinzerling, K. G., Chim, D., Annon, J. J., Dowling, P. T., & Doraimani, G. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03619.x · Cited by 35
Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications
Verrico, C. D., Haile, C. N., Newton, T. F., Kosten, T. R., & Garza, R. D. L. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.836488 · Cited by 34
Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials
Pérez-Mañá, C., Castells, X., Vidal, X., Casas, M., & Capellà, D. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.08.012 · Cited by 33
Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.040 · Cited by 34
Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys.
Schindler, C. W., Gilman, J. P., Panlilio, L. V., McCann, D. J., & Goldberg, S. R. (2011) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0022432 · Cited by 32
Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine
Stoops, W. W., Pike, E., Hays, L. R., Glaser, P. E. A., & Rush, C. R. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.11.018 · Cited by 32
Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men
Das, M., Santos, D., Matheson, T., Santos, G., Chu, P. L., Vittinghoff, E., SHOPTAW, S. J., & Colfax, G. N. (2010) · AIDS · doi:10.1097/qad.0b013e328336e98b · Cited by 33
Glutamatergic Neurometabolites during Early Abstinence from Chronic Methamphetamine Abuse
O’Neill, J., Tobias, M. C., Hudkins, M. R., & London, E. D. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu059 · Cited by 32
A Study of the Prevalence of Psychiatric Disorders in Patients with Methamphetamine-Induced Psychosis.
Shahrbabaki, M. E., Fekrat, A., & Mazhari, S. (2015) · Europe PMC (PubMed Central) · Cited by 31
Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups
Soares, E. F. P., & Pereira, F. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1681970 · Cited by 31
Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study
Egerton, A., Shotbolt, J. P., Stokes, P. R. A., Hirani, E., Ahmad, R., Lappin, J., Reeves, S., Mehta, M. A., Howes, O. D., & Grasby, P. M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.077 · Cited by 33
The Effect of Buprenorphine and Bupropion in the Treatment of Methamphetamine Dependency and Craving
Ahmadi, J. (2015) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2015/19334 · Cited by 28
The Effect of Buprenorphine on Methamphetamine Cravings
Salehi, M., Emadossadat, A., Kheirabadi, G. R., Maracy, M. R., & Maracy, M. R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000408 · Cited by 28
Gender, Brain-Derived Neurotrophic Factor Val66Met, and Frequency of Methamphetamine Use
Heinzerling, K. G., & SHOPTAW, S. J. (2012) · Gender Medicine · doi:10.1016/j.genm.2012.02.005 · Cited by 28
Taurine protects methamphetamine-induced developmental angiogenesis defect through antioxidant mechanism
Shao, X., Hu, Z., Hu, C., Bu, Q., Yan, G., Deng, P., Lv, L., Wu, D., Deng, Y., Zhao, J., et al. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.03.003 · Cited by 28
Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers
Verrico, C. D., Mahoney, J. J., Thompson-Lake, D. G. Y., Bennett, R. S., Newton, T. F., & Garza, R. D. L. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571300134x · Cited by 26
Pharmacotherapy treatment of stimulant use disorder
Liu, M. T. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.11.347 · Cited by 20
Pilot Randomized Trial of Bupropion for Adolescent Methamphetamine Abuse/Dependence
Heinzerling, K. G., Gadzhyan, J., van Oudheusden, H., Rodriguez, F., McCracken, J. T., & SHOPTAW, S. J. (2013) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2012.10.275 · Cited by 26
The Effects of Methylphenidate on Cognitive Control in Active Methamphetamine Dependence Using Functional Magnetic Resonance Imaging
Jan, R. K., Lin, J. C., McLaren, D. G., Kirk, I. J., Kydd, R. R., & Russell, B. R. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00020 · Cited by 26

Authors: Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., Pearce, V. J., McCann, M., Campbell, J., Gorodetzky, C., Haning, W., Carlton, B., Mawhinney, J., & Weis, D.
Affiliations: National Institutes of Health (US)
University of California, Los Angeles (US)
Stanford Medicine (US)
Matrix Institute on Addictions (US)
University of Missouri–Kansas City (US)
IQVIA (United Kingdom) (GB)
University of Hawaiʻi at Mānoa (US)
Corresponding author: Elkashef, Ahmed M
ORCID: Elkashef, Ahmed M
Rawson, Richard A
Holmes, Tyson
Vocci, Frank
Ling, Walter
McCann, Michael
Carlton, Barry
Venue: Neuropsychopharmacology
Publisher: Springer Science and Business Media LLC
Published: 2007-06-20
Volume: 33
Issue: 5
Pages: 1162-1170
ISSN: 0893-133X (ISSN-L)
1740-634X
DOI: 10.1038/sj.npp.1301481
OpenAlex: W2003590685
Cited by: 234
References: 42
Citations by year: 2026: 12 · 2025: 7 · 2024: 8 · 2023: 13 · 2022: 9 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 10 · 2017: 8 · 2016: 15 · 2015: 16 · 2014: 22 · 2013: 19 · 2012: 14
FWCI: 10.78
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Neuropsychopharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Drug Abuse (N01DA-3-8824, N01-DA-0-8804)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: bupropion, methamphetamine dependence, cocaine dependence, abstinence, bupropion sustained release, group therapy, comorbid depression, attention deficit hyperactivity disorder, craving, HIV risk behavior, substance use disorders
MeSH terms: Adult, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Methamphetamine, Middle Aged, Mississippi, Psychotherapy, Severity of Illness Index, Bupropion, Treatment Outcome, Dopamine Uptake Inhibitors, Amphetamine-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bupropion for the Treatment of Methamphetamine Dependence

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks